Hugosson J, et al. - Researchers conducted this multicentre population-based randomised screening trial to ascertain if prostate-specific antigen (PSA) screening decreases prostate cancer (PCa) mortality for up to 16 yr and to evaluate results following adjustment for nonparticipation and the number of screening rounds attended. The report includes 182,160 males, followed up to 2014 (up to 16 years), with a predefined core age group of 162,389 males (55–69 yr), chosen from the population registry. Data reported that the rate ratio of PCa mortality was 0.80 at 16 yr. Earlier findings confirm that PSA screening significantly reduces PCa mortality, showing greater absolute benefit with longer follow-up and a reduction in excess incidence. Repeated screening may be important for reducing population-level PCa mortality.